News
Why Novavax, Inc Is Tanking Today
After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.Here's a
3 Stocks That Could Be Life-Changers
As the saying goes, "If there's no risk, there's no reward." No investment is without risk, but stocks that have life-changing potential tend to come with higher risks than your average investment. Of
3 Dividend Stocks That Thrive in Bear Markets
If you're looking to outsmart bears the next time they come knocking, you might want to consider adding PepsiCo (NYSE: PEP), Gilead Sciences (NASDAQ: GILD), and Colgate-Palmolive (NYSE: CL) to your
3 Key Things Every CAR-T Investor Should Watch
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.First-to-market advantage will likely to go Novartis
Corning Looks to Sustain Its Momentum
Corning Incorporated (NYSE: GLW) is set to announce second-quarter 2017 results this Wednesday, July 26, 2017. With shares trading at a 10-year high after climbing more than 30% year to date as of
Why Novavax Stock Spiked Today
Shares of the clinical-stage vaccine-maker Novavax (NASDAQ: NVAX) gained as much as 18.2% today on sky-high volume. This noteworthy uptick was sparked by the anticipation surrounding the company's
Why Reata Pharmaceuticals Is Rallying 17.5% Today
Reata Pharmaceuticals (NASDAQ: RETA) shares were surging 17.5% higher at 3 p.m. EST today, after the company reported that its experimental drug bardoxolone improved kidney function in patients with
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
Why ImmunoGen, Inc. Jumped Higher Today
ImmunoGen (NASDAQ: IMGN) closed up 12% today on no apparent good news. In fact, there was a bit of bad news on Friday after partner Bayer revealed that anetumab ravtansine, which ImmunoGen helped
Why NeuroDerm Ltd Acquired a Higher Price Today
NeuroDerm (NASDAQ: NDRM) is up 15.5% at 12:05 p.m. EDT after announcing that it will be acquired by Japan-based Mitsubishi Tanabe Pharma for $39 per share. The deal puts the value of the biotech at
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE: PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, Pfizer makes some of
3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock)
Not every stock that falls on tough times is worth buying in portfolios, but sometimes, catalysts can spark shareholder-friendly rallies, and in those situations, it can make sense. For example
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present
Should Investors Brace for Bad News From Novavax's Looming Clinical Update?
One press release last week caused shares of clinical-stage biotech Novavax (NASDAQ: NVAX) to soar nearly 25%. The company didn't announce an FDA approval. It didn't even report results from a
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price is
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls
Here's How to Find the Best Dividend Stocks
Finding great income stocks would be easy if the only metric that mattered was yield. If that was true, then an investor would simply screen for the highest-yielding stocks they could find and buy
It Took Just 10 Days for Nevada's Recreational Marijuana Industry to Fall Into a State of Emergency
When discussing the fastest-growing industries on the planet, few, or none, may top the legal marijuana industry. According to cannabis research group ArcView, North American legal pot sales are
2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared
3 Been-There-Done-That Biotech CEOs Who Are Doing it Again
You might want to turn back the clock so that you can profit from Puma Biotechnology's (NASDAQ: PBYI) 212% return this year, but unfortunately, you can't. Instead, you'll just have to go out and find
Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences
When it comes to the high-flying healthcare sector, there aren't many bargains to be had. President Trump's recent change of heart regarding the possibility of hard caps on high-priced prescription
3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?
Biotechnology's top performing stocks this year have already given investors envy-inspiring returns, but there's reason to believe that Calithera Biosciences (NASDAQ: CALA), Aurinia Pharmaceuticals
Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says?
In this segment from Rule Breaker Investing, Motley Fool co-founder David Gardner attempts to answer a Foolish investor who is skeptical that the leadership ability and style of CEOs and executive
Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today
Stocks didn't move much on Thursday, and major benchmarks were narrowly mixed as earnings season kicked into full gear. Healthcare and utility stocks were generally higher, but the industrials and